{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:08:34Z","timestamp":1785802114535,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94556-3","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:24:42Z","timestamp":1742819082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission"],"prefix":"10.1038","volume":"15","author":[{"given":"Mengnan","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"94556_CR1","unstructured":"1. Hematology Oncology Committee, C.A.-C.A., Leukemia, and C.S.o.H.C.M.A. Lymphoma Group, [Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)]. Zhonghua Xue Ye Xue Za Zhi, 2021. 42(9): p. 705\u2013716."},{"key":"94556_CR2","doi-asserted-by":"crossref","unstructured":"2. G\u00f6kbuget, N., et al., Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 2012. 120(10): p. 2032-41.","DOI":"10.1182\/blood-2011-12-399287"},{"key":"94556_CR3","doi-asserted-by":"crossref","unstructured":"3. Khimani, F., et al., Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther, 2021. 27(7): p. 620.e1-620.e9.","DOI":"10.1016\/j.jtct.2021.03.026"},{"key":"94556_CR4","doi-asserted-by":"crossref","unstructured":"4. Girinsky, T., et al., Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol, 2000. 18(5): p. 981-6.","DOI":"10.1200\/JCO.2000.18.5.981"},{"key":"94556_CR5","doi-asserted-by":"crossref","unstructured":"5. Banet, A., et al., Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. Bone Marrow Transplant, 2023. 58(1): p. 61\u201367.","DOI":"10.1038\/s41409-022-01841-0"},{"key":"94556_CR6","doi-asserted-by":"crossref","unstructured":"6. Mitsuhashi, K., et al., Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant, 2016. 22(12): p. 2194\u20132200.","DOI":"10.1016\/j.bbmt.2016.09.007"},{"key":"94556_CR7","doi-asserted-by":"crossref","unstructured":"7. Kebriaei, P., et al., Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant, 2013. 48(1): p. 26\u201331.","DOI":"10.1038\/bmt.2012.114"},{"key":"94556_CR8","doi-asserted-by":"crossref","unstructured":"8. Gooptu, M., et al., A Comparison of the Myeloablative Conditioning Regimen Fludarabine\/Busulfan with Cyclophosphamide\/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant, 2018. 24(8): p. 1733\u20131740.","DOI":"10.1016\/j.bbmt.2018.03.011"},{"key":"94556_CR9","doi-asserted-by":"crossref","unstructured":"9. Zhang, H., et al., Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol, 2023. 41(2): p. 343\u2013353.","DOI":"10.1200\/JCO.22.00767"},{"key":"94556_CR10","doi-asserted-by":"crossref","unstructured":"10. Sakellari, I., et al., Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. Ann Hematol, 2018. 97(10): p. 1987\u20131994.","DOI":"10.1007\/s00277-018-3383-9"},{"key":"94556_CR11","doi-asserted-by":"crossref","unstructured":"11. Wang, Y.H., et al., Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. Cancer Rep (Hoboken), 2022. 5(3): p. e1488.","DOI":"10.1002\/cnr2.1488"},{"key":"94556_CR12","doi-asserted-by":"crossref","unstructured":"12. Rehman, M.E.U., et al., Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk, 2023. 23(4): p. 249\u2013258.","DOI":"10.1016\/j.clml.2023.01.004"},{"key":"94556_CR13","doi-asserted-by":"crossref","unstructured":"13. Friend, B.D., et al., The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer, 2020. 67(2): p. e28079.","DOI":"10.1002\/pbc.28079"},{"key":"94556_CR14","doi-asserted-by":"crossref","unstructured":"14. Lv, M., et al., Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. Br J Haematol, 2023. 202(2): p. 369\u2013378.","DOI":"10.1111\/bjh.18846"},{"key":"94556_CR15","doi-asserted-by":"crossref","unstructured":"15. Bazarbachi, A., et al., 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res, 2022. 28(5): p. 1004\u20131012.","DOI":"10.1158\/1078-0432.CCR-21-2675"},{"key":"94556_CR16","doi-asserted-by":"crossref","unstructured":"16. Ben Hassine, K., et al., Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. Front Pediatr, 2021. 9: p. 775485.","DOI":"10.3389\/fped.2021.775485"},{"key":"94556_CR17","doi-asserted-by":"crossref","unstructured":"17. Mardani, M., et al., Total body irradiation-free haploidentical peripheral blood stem cell transplantation compared to related and unrelated donor transplantation in pediatrics with acute lymphoblastic leukemia. Pediatr Blood Cancer, 2023. 70(5): p. e30255.","DOI":"10.1002\/pbc.30255"},{"key":"94556_CR18","doi-asserted-by":"crossref","unstructured":"18. Niu, J., et al., Total Body Irradiation-Based Conditioning Regimen Improved the Survival of Adult Patients With T-Cell Lymphoblastic Lymphoma After Allogeneic Peripheral Blood Stem Cell Transplantation. Cell Transplant, 2022. 31: p. 9636897221108890.","DOI":"10.1177\/09636897221108890"},{"key":"94556_CR19","doi-asserted-by":"crossref","unstructured":"19. Cahu, X., et al., Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant, 2016. 51(3): p. 351-7.","DOI":"10.1038\/bmt.2015.278"},{"key":"94556_CR20","doi-asserted-by":"crossref","unstructured":"20. Dholaria, B., et al., Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplant Cell Ther, 2021. 27(2): p. 171.e1-171.e8.","DOI":"10.1016\/j.jtct.2020.10.008"},{"key":"94556_CR21","doi-asserted-by":"crossref","unstructured":"21. Kebriaei, P., et al., Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant, 2018. 24(4): p. 726\u2013733.","DOI":"10.1016\/j.bbmt.2017.11.025"},{"key":"94556_CR22","doi-asserted-by":"crossref","unstructured":"22. Peters, C., et al., Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol, 2021. 39(4): p. 295\u2013307.","DOI":"10.1200\/JCO.20.02529"},{"key":"94556_CR23","doi-asserted-by":"crossref","unstructured":"23. McDonald, A.M., et al., Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. J Clin Oncol, 2020. 38(25): p. 2872\u20132882.","DOI":"10.1200\/JCO.20.00231"},{"key":"94556_CR24","doi-asserted-by":"crossref","unstructured":"24. Andersen, J., et al., Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation. Bone Marrow Transplant, 2006. 37(7): p. 635\u2009\u2212\u200940.","DOI":"10.1038\/sj.bmt.1705295"},{"key":"94556_CR25","doi-asserted-by":"crossref","unstructured":"25. Czyz, A. and A. Nagler, The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Int J Mol Sci, 2019. 20(21).","DOI":"10.3390\/ijms20215362"},{"key":"94556_CR26","doi-asserted-by":"crossref","unstructured":"26. Bar, M., et al., Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment, 2014. 2014: p. 421723.","DOI":"10.1155\/2014\/421723"},{"key":"94556_CR27","doi-asserted-by":"crossref","unstructured":"27. Shen, Z., et al., Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer, 2018. 18(1): p. 755.","DOI":"10.1186\/s12885-018-4670-5"},{"key":"94556_CR28","doi-asserted-by":"crossref","unstructured":"28. Zhao, X.S., et al., Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol, 2019. 94(5): p. 512\u2013521.","DOI":"10.1002\/ajh.25417"},{"key":"94556_CR29","doi-asserted-by":"crossref","unstructured":"29. Shi, Z., et al., Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology, 2022. 27(1): p. 642\u2013652.","DOI":"10.1080\/16078454.2022.2074704"},{"key":"94556_CR30","doi-asserted-by":"crossref","unstructured":"30. Deak, D., et al., Let\u2019s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Front Immunol, 2019. 10: p. 2856.","DOI":"10.3389\/fimmu.2019.02856"},{"key":"94556_CR31","doi-asserted-by":"crossref","unstructured":"31. Sun, W. and X. Huang, Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. Chin Med J (Engl), 2022. 135(8): p. 890\u2013900.","DOI":"10.1097\/CM9.0000000000001898"},{"key":"94556_CR32","doi-asserted-by":"crossref","unstructured":"32. Handgretinger, R. and P. Lang, Could (should) we abandon total body irradiation for conditioning in children with leukemia. Blood Rev, 2022. 56: p. 100966.","DOI":"10.1016\/j.blre.2022.100966"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94556-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:25:06Z","timestamp":1742819106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94556"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94556-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethics committees of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College according to the guidelines of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Written informed consent was obtained for each patients according to federal and institutional guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}],"article-number":"10079"}}